Paraganglioma Clinical Trials Paraganglioma RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor Intervention:   Drug: MK-6482 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2021 Category: Research Source Type: clinical trials